China’s bio-Medicine company Akesobio raised nearly $150 million in a series D round funding led by Loyal valley Capital and SinoBiopharmaceutical Limited, and followed by Shenzhen Capital Group, LAKE BLEU Healthcre Fund, Shenzhen G-cinda Technology- Dongwu Overseas Fund, AIHC, Orbimed, K. Wah Group, ccb Capital, Apricot Capital, TRI Wise, BOCOM International , and other famous investment institutions. The investment will be used to advance research on its innovative drugs and clinical development.
Established in 2012, Akesobio is committed to the discovery and development of innovative antibody drugs with self IP. Its has build an international bio-medicine platform covering the whole process of R&D and commercialization. It has product lines targeting tumors, autoimmune diseases, inflammation, and angiocardiopathy.
South Africa Today